C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $16,431,949 | -31.1% | 3,556,699 | +21.8% | 0.00% | – |
Q1 2024 | $23,856,629 | +111.2% | 2,920,028 | +46.0% | 0.00% | – |
Q4 2023 | $11,296,616 | +215.5% | 1,999,401 | +3.9% | 0.00% | – |
Q3 2023 | $3,580,232 | -31.5% | 1,924,856 | +1.3% | 0.00% | – |
Q2 2023 | $5,225,979 | -21.2% | 1,900,356 | -10.0% | 0.00% | – |
Q1 2023 | $6,633,331 | -45.6% | 2,112,526 | +2.3% | 0.00% | – |
Q4 2022 | $12,182,998 | -31.2% | 2,064,915 | +2.2% | 0.00% | -100.0% |
Q3 2022 | $17,711,000 | +19.8% | 2,019,654 | +3.0% | 0.00% | – |
Q2 2022 | $14,783,000 | -69.9% | 1,960,713 | -3.0% | 0.00% | -100.0% |
Q1 2022 | $49,057,000 | -24.4% | 2,022,142 | +0.3% | 0.00% | 0.0% |
Q4 2021 | $64,929,000 | -25.0% | 2,016,459 | +4.0% | 0.00% | -50.0% |
Q3 2021 | $86,616,000 | +62.7% | 1,938,575 | +37.8% | 0.00% | +100.0% |
Q2 2021 | $53,234,000 | +270.9% | 1,406,840 | +262.6% | 0.00% | – |
Q1 2021 | $14,351,000 | -4.2% | 387,958 | -14.2% | 0.00% | – |
Q4 2020 | $14,980,000 | – | 452,167 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |